# Chronic Obstructive Pulmonary Disease (COPD) Research

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the standardisation, diagnosis, and management of Chronic Obstructive Pulmonary Disease (COPD), including the use of spirometry for lung function testing, global burden analysis, exacerbation frequency, and the development of guidelines for treatment and prevention. It also explores the relationship between COPD and systemic inflammation, comorbidities, and mortality. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10143 |
| Works | 505 |

## Topic papers all

Showing 15 of 505.

- [Rules for Scoring Respiratory Events in Sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events](https://scholariq.org/papers/rules-for-scoring-respiratory-events-in-sleep-update-of-the-2007-aasm-manual-for/)
- [2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)](https://scholariq.org/papers/2019-esc-guidelines-for-the-diagnosis-and-management-of-acute-pulmonary-embolism/)
- [Development and first validation of the COPD Assessment Test](https://scholariq.org/papers/development-and-first-validation-of-the-copd-assessment-test/)
- [Driving Pressure and Survival in the Acute Respiratory Distress Syndrome](https://scholariq.org/papers/driving-pressure-and-survival-in-the-acute-respiratory-distress-syndrome/)
- [Bosentan Therapy for Pulmonary Arterial Hypertension](https://scholariq.org/papers/bosentan-therapy-for-pulmonary-arterial-hypertension/)
- [A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension](https://scholariq.org/papers/a-comparison-of-continuous-intravenous-epoprostenol-prostacyclin-with/)
- [Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015](https://scholariq.org/papers/global-regional-and-national-deaths-prevalence-disability-adjusted-life-years/)
- [An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease](https://scholariq.org/papers/an-official-european-respiratory-society-american-thoracic-society-technical/)
- [International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study](https://scholariq.org/papers/international-variation-in-the-prevalence-of-copd-the-bold-study-a-population/)
- [Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017](https://scholariq.org/papers/prevalence-and-attributable-health-burden-of-chronic-respiratory-diseases-1990/)
- [An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline](https://scholariq.org/papers/an-official-ats-ers-jrs-alat-clinical-practice-guideline-treatment-of-idiopathic/)
- [Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension](https://scholariq.org/papers/expression-of-endothelin-1-in-the-lungs-of-patients-with-pulmonary-hypertension/)
- [Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health \[CPH\] study): a national cross-sectional study](https://scholariq.org/papers/prevalence-and-risk-factors-of-chronic-obstructive-pulmonary-disease-in-china/)
- [Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension](https://scholariq.org/papers/macitentan-and-morbidity-and-mortality-in-pulmonary-arterial-hypertension/)
- [Outcomes Following Acute Exacerbation of Severe Chronic Obstructive Lung Disease. The SUPPORT Investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)](https://scholariq.org/papers/outcomes-following-acute-exacerbation-of-severe-chronic-obstructive-lung-disease/)

## Topic primary papers

Showing 15 of 216.

- [Development and first validation of the COPD Assessment Test](https://scholariq.org/papers/development-and-first-validation-of-the-copd-assessment-test/)
- [Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015](https://scholariq.org/papers/global-regional-and-national-deaths-prevalence-disability-adjusted-life-years/)
- [An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease](https://scholariq.org/papers/an-official-european-respiratory-society-american-thoracic-society-technical/)
- [International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study](https://scholariq.org/papers/international-variation-in-the-prevalence-of-copd-the-bold-study-a-population/)
- [Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017](https://scholariq.org/papers/prevalence-and-attributable-health-burden-of-chronic-respiratory-diseases-1990/)
- [Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health \[CPH\] study): a national cross-sectional study](https://scholariq.org/papers/prevalence-and-risk-factors-of-chronic-obstructive-pulmonary-disease-in-china/)
- [Outcomes Following Acute Exacerbation of Severe Chronic Obstructive Lung Disease. The SUPPORT Investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)](https://scholariq.org/papers/outcomes-following-acute-exacerbation-of-severe-chronic-obstructive-lung-disease/)
- [An Official American Thoracic Society Public Policy Statement: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease](https://scholariq.org/papers/an-official-american-thoracic-society-public-policy-statement-novel-risk-factors/)
- [An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease](https://scholariq.org/papers/an-official-systematic-review-of-the-european-respiratory-society-american/)
- [Comparison of Computed Density and Macroscopic Morphometry in Pulmonary Emphysema](https://scholariq.org/papers/comparison-of-computed-density-and-macroscopic-morphometry-in-pulmonary/)
- [Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019](https://scholariq.org/papers/burden-of-chronic-obstructive-pulmonary-disease-and-its-attributable-risk/)
- [American Thoracic Society Statement: Occupational Contribution to the Burden of Airway Disease](https://scholariq.org/papers/american-thoracic-society-statement-occupational-contribution-to-the-burden-of/)
- [ERS statement on respiratory muscle testing at rest and during exercise](https://scholariq.org/papers/ers-statement-on-respiratory-muscle-testing-at-rest-and-during-exercise/)
- [Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019](https://scholariq.org/papers/global-burden-of-chronic-respiratory-diseases-and-risk-factors-1990-2019-an/)
- [Computed Tomographic Measurements of Airway Dimensions and Emphysema in Smokers](https://scholariq.org/papers/computed-tomographic-measurements-of-airway-dimensions-and-emphysema-in-smokers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.